Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Pitcairn Co.

Pitcairn Co. reduced its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 30.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,995 shares of the biotechnology company’s stock after selling 9,508 shares during the period. Pitcairn Co.’s holdings in Aurinia Pharmaceuticals were worth $487,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of AUPH. Selective Wealth Management Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter worth approximately $33,000. Geneos Wealth Management Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 717.1% during the 3rd quarter. Geneos Wealth Management Inc. now owns 2,108 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 1,850 shares during the last quarter. Private Capital Group LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 39.0% during the 3rd quarter. Private Capital Group LLC now owns 2,072 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 581 shares during the last quarter. Total Clarity Wealth Management Inc. acquired a new position in Aurinia Pharmaceuticals in the third quarter valued at approximately $48,000. Finally, Northern Oak Wealth Management Inc. lifted its holdings in Aurinia Pharmaceuticals by 60.0% in the second quarter. Northern Oak Wealth Management Inc. now owns 4,800 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 1,800 shares during the last quarter. Institutional investors and hedge funds own 33.89% of the company’s stock.

In other news, insider Michael Robert Martin sold 40,000 shares of the stock in a transaction dated Thursday, November 11th. The shares were sold at an average price of $29.01, for a total transaction of $1,160,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jill Leversage bought 1,600 shares of the firm’s stock in a transaction dated Monday, December 13th. The shares were acquired at an average price of $20.04 per share, with a total value of $32,064.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 265,000 shares of company stock worth $7,960,200. Corporate insiders own 3.10% of the company’s stock.

A number of research analysts recently commented on AUPH shares. Jefferies Financial Group reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, December 15th. SVB Leerink upped their price target on Aurinia Pharmaceuticals from $28.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, November 4th. Oppenheimer upgraded Aurinia Pharmaceuticals from a “market perform” rating to an “outperform” rating and decreased their price target for the stock from $33.00 to $31.00 in a research note on Friday, December 10th. Royal Bank of Canada upped their price target on Aurinia Pharmaceuticals from $23.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 26th. Finally, Bloom Burton assumed coverage on Aurinia Pharmaceuticals in a research note on Friday, October 1st. They set a “hold” rating and a $23.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.83.

NASDAQ:AUPH opened at $19.71 on Friday. The firm has a market capitalization of $2.53 billion, a PE ratio of -16.29 and a beta of 0.70. The business’s fifty day moving average price is $22.19 and its 200 day moving average price is $19.61. Aurinia Pharmaceuticals Inc. has a 12 month low of $9.72 and a 12 month high of $33.97.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.06). The business had revenue of $14.67 million during the quarter, compared to analysts’ expectations of $14.70 million. Aurinia Pharmaceuticals had a negative net margin of 215.58% and a negative return on equity of 44.22%. During the same period last year, the company earned ($0.28) EPS. On average, equities research analysts anticipate that Aurinia Pharmaceuticals Inc. will post -1.42 EPS for the current fiscal year.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Featured Story: What is the CAC 40 Index?

Want to see what other hedge funds are holding AUPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP).

Institutional Ownership by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.